attenuates the hypoglycemia-induced reflex increase of epinephrine (Epi). To examine the role of brain AT 1 and AT 2 receptors in the reflex regulation of Epi release, we measured catecholamines, hemodynamics, and renin during insulininduced hypoglycemia in conscious rats pretreated intracerebroventricularly with losartan, PD-123319, losartan and PD-123319, or vehicle. Epi and norepinephrine (NE) increased 60-and 3-fold, respectively. However, the gain of the reflex increase in plasma Epi (⌬plasma Epi/⌬plasma glucose) and the overall Epi and NE responses were similar in all groups. The ensuing blood pressure response was similar between groups, but the corresponding bradycardia was augmented after PD-123319 (P Ͻ 0.05 vs. vehicle) or combined losartan and PD-123319 (P Ͻ 0.01 vs. vehicle). The findings indicate 1) brain angiotensin receptors are not essential for the reflex regulation of Epi release during hypoglycemia and 2) the gain of baroreceptor-mediated bradycardia is increased by blockade of brain AT 2 receptors in this model. losartan; PD-123319; epinephrine; baroreflex INSULIN-INDUCED HYPOGLYCEMIA powerfully stimulates sympathoadrenal activity and hence epinephrine (Epi) release. Thus, in rats, severe hypoglycemia elicits an ϳ60-fold increase in the plasma concentration of Epi (35). This is considered an important counter-regulatory response during severe hypoglycemia. Therefore, any substance or maneuver that impairs this reflex increase in Epi release may potentially worsen or predispose patients with diabetes mellitus to episodes of hypoglycemia (10).
INSULIN-INDUCED HYPOGLYCEMIA powerfully stimulates sympathoadrenal activity and hence epinephrine (Epi) release. Thus, in rats, severe hypoglycemia elicits an ϳ60-fold increase in the plasma concentration of Epi (35) . This is considered an important counter-regulatory response during severe hypoglycemia. Therefore, any substance or maneuver that impairs this reflex increase in Epi release may potentially worsen or predispose patients with diabetes mellitus to episodes of hypoglycemia (10) .
Several lines of evidence suggest that angiotensin II stimulates or facilitates adrenomedullary Epi release. Thus exogenous angiotensin II stimulates Epi secretion in vivo (24) , and high concentrations of angiotensin II stimulate Epi release from isolated perfused adrenals (33) . Furthermore, nonselective angiotensin II receptor blockade with [Sar,Ile]-angiotensin abolishes adrenomedullary catecholamine release during insulin-induced hypoglycemia (4) . We showed that the increase in plasma Epi concentration during insulininduced hypoglycemia is unaltered by selective AT 1 -receptor blockade in both rats and humans (34, 35) . However, we also found that simultaneous AT 1 -and AT 2 -receptor blockade or systemic ACE-inhibition significantly attenuates the reflex increase in Epi during insulin-induced hypoglycemia (14, 35) . This suggests that angiotensin II interacts with Epi release either by an AT 2 receptor-mediated action or by a mechanism that involves both AT 1 and AT 2 receptors. However, these in vivo findings disagree with some in vitro studies on isolated perfused rat adrenal glands, which suggest that AT 1 -receptor blockade, but not AT 2 -receptor blockade, attenuates the Epi release elicited by exogenous angiotensin II (33) .
Hypothalamic glucose-sensitive sensory neurons project to spinal neural pathways that are paramount for adrenal sympathetic nerve activity and Epi release (17) . AT 1 and AT 2 receptors have been identified in brain areas involved in the central regulation of cardiovascular function (7, 19) . Moreover, AT 1 and AT 2 receptors are present in the spinal cord, and functional studies suggest that both subtypes are involved in the pressor response to intrathecal administration of angiotensin II (22, 23) . In the adrenal medulla, the AT 2 receptor is abundant and constitutes Ͼ90% of the angiotensin receptors (2, 3, 5) . Thus angiotensin II may modify the hypoglycemia-induced increase in adrenal sympathetic nerve activity and Epi release through different subtypes of angiotensin receptors at different neural levels involved in this reflex response. This may explain the discrepancies between the above-mentioned in vitro and in vivo studies, because systemic administration of angiotensin receptor antagonists af-fects receptors in both the central nervous system and in the adrenal medulla (22, 26) , whereas only adrenomedullary angiotensin receptors were blocked in the in vitro studies.
The aim of this study was to examine if endogenous angiotensin II modifies the hypoglycemia-induced reflex increase in Epi release by an action in the central nervous system. Plasma concentrations of catecholamines, blood pressure, heart rate, and renin activity were measured during insulin-induced hypoglycemia in chronically instrumented, conscious rats pretreated with intracerebroventricular losartan (AT 1 -receptor blockade), PD-123319 (AT 2 -receptor blockade), combined AT 1 -and AT 2 -receptor blockade (losartan ϩ PD-123319), or vehicle.
METHODS

Materials
Male Sprague-Dawley rats (300 g) were purchased from Møllegården, Lille Skendsved, Denmark. Rats were housed individually at the Panum Institute animal care facility in rooms with constant humidity and temperature and a 12: 12-h light-dark cycle. Animals had free access to tap water and a commercial standard rat diet (Altromin catalog no. C 1314, Altromin International, Lage, Germany). Experiments were performed in compliance with the ethical code for laboratory animal care issued by the Danish Ministry of Justice.
Animal Preparation
Surgical procedures were performed during neurolept anesthesia induced by a subcutaneously injected mixture of (in mg/kg) 0.2 fentanyl, 6.7 fluanizone, and 3.4 midazolam. Permanent Tygon catheters were inserted into the abdominal aorta and into the inferior caval vein using aseptic techniques. Catheters were tunneled subcutaneously to the back of the neck, where they were fixed. To ensure long-term patency, catheters were filled with a solution containing 50% glucose added to 1,000 IU heparin /ml and 7,500 IU streptokinase/ml. After 24 h of recovery, a stainless steel cannula (Plastics One, Roanoke, VA) was inserted in the right lateral cerebral ventricle situated at the coordinates 0.9 mm posterior to bregma, 1.4 mm lateral to the midline, and 4.7 mm below the skull surface. At least 7 days of recovery were allowed before the experiment.
Experimental Protocol
Rats were fasted overnight before the experiments, which were performed in a quiet laboratory environment. The rat was placed in the experimental cage and allowed an equilibration period of at least 30 min duration. Then the rats were randomized to intracerebroventricular pretreatment with either vehicle (isotonic saline 4 l; n ϭ 12), the AT 1 -receptor antagonist losartan (10 nmol in 2 l ϩ 2 l vehicle; n ϭ 12), the AT 2 -receptor antagonist PD-123319 (30 nmol in 2 l ϩ 2 l vehicle; n ϭ 12), or combined AT 1 -and AT 2 -receptor blockade (losartan, 10 nmol in 2 l ϩ PD-123319, 30 nmol in 2 l; n ϭ 12). After 20 min, a reference blood sample (time 0) was drawn to determine plasma concentrations of glucose, Epi, NE, and plasma renin activity (PRA). Then hypoglycemia was induced by intravenous administration of insulin, 4 IU/kg, and arterial blood samples were drawn every 7.5 min for the next 30 min, and at 45 and 60 min after insulin administration to determine plasma glucose, Epi, and NE.
PRA was redetermined at time 45 min, when plasma catecholamine concentrations were near maximal. Blood samples (250 l each) were drawn into chilled test tubes containing 1 mg EGTA and 0.7 mg reduced glutathione and kept on ice during handling. The blood was centrifuged at 4°C for 10 min, and plasma was stored at Ϫ20°C until analysis. All blood samples were immediately replaced by intravenous infusion of fresh donor blood obtained from littermates that were pair fasted overnight. To verify accurate placement of the intracerebroventricular cannula, each rat was sedated with intravenous pentobarbital sodium at the end of the experiment. Five microliters of black ink was injected intracerebroventricularly and allowed 15 min for diffusion into the cerebrospinal fluid and adjacent brain tissue. Then the rat was killed with an intravenous overdose of pentobarbital sodium, and correct placement of the cannula was verified by staining of all ventricles and the base of the brain. On the basis of this test, three rats were discarded due to uneven distribution of stain. To determine the efficacy and confinement of intracerebroventricular administration of the AT 1 -receptor antagonist to brain angiotensin receptors, six additional rats were prepared with chronic catheters and intracerebroventricular cannulas. In these animals, the blood pressure response to intracerebroventricular and intravenous administered angiotensin II was determined before and after intracerebroventricular administration of losartan.
Blood Pressure and Heart Rate Recording
Mean arterial pressure (MAP) was measured continuously with a pressure transducer (Statham P23 XL) and displayed on a Grass model 7D polygraph. Heart rate (HR) was recorded by a linear cardiotachometer (Grass model 7P4) triggered by the arterial pressure waveform. Analog signals were digitized using an AT-MIO-16XE-50 board (National Instruments) and sampled at 1,000 Hz using a data-acquisition program written in LabView (National Instruments), recorded and stored as described previously (35) .
Biochemical Analyses
Plasma glucose concentrations were determined on a model 6517 Glucose analyzer II (Beckman Instruments, Fullerton, CA). Determination of plasma catecholamine concentrations was done using high-pressure liquid chromatographic separation of radioenzymatically labeled catecholamines. Intra-and interassay coefficients of variation for Epi were 4 and 10%, and those for NE were 4 and 8%, respectively. PRA was determined as described previously (35) . All analyses were done in duplicate.
Drugs
Insulin (Novo Nordisk, Gentofte, Denmark), 4 IU/ml, was dissolved in isotonic saline with 1% human serum albumin added and stored at 5°C. Losartan (Du Pont Pharmaceuticals, Wilmington, DE) and PD-123319 (Parke-Davis, Ann Arbor, MI) were dissolved in isotonic saline to final concentrations of 5 and 15 nmol/l, respectively. Angiotensin II (Sigma, St. Louis, MO) was dissolved in isotonic saline to final concentrations of 2 nmol/ml and 50 pmol/l for intravenous and intracerebroventricular administration, respectively.
Data Analysis
Hemodynamics. Data on MAP and HR are average values during the last 60 s preceding disconnection of the arterial catheter for blood sampling. Comparisons between groups were performed using two-way ANOVA for repeated measurements. The HR response to the MAP increase differed significantly between groups. Thus corresponding data pairs of ⌬MAP and ⌬HR for each animal were plotted, and the slope of the "baroreceptor" curves was obtained using linear regression. Then the slopes of the regression lines were compared between selected groups using one-way ANOVA.
Catecholamines. Time course evolution of plasma Epi and NE during the entire hypoglycemic period (time 0-60 min) were compared using two-way ANOVA for repeated measurements. The relationship between corresponding plasma glucose and plasma Epi concentrations during the period of increasing Epi (time 7.5-30 min) represented the gain of the reflex. With the least-square regression method, corresponding data pairs of glucose and Epi concentrations were fitted with the index function
. Then parameters log a and k of that function as well as area under the entire concentration vs. time curves (AUCs) were compared using one-way ANOVA. Statistical analysis was performed using the software package Statistica version 6.0 (Statsoft, Tulsa, OK). Plasma concentrations of Epi and NE were logarithmically transformed to obtain normal distribution of data before statistical analysis. A probability level of P Ͻ 0.05 was considered significant. Presented values are means Ϯ SE.
RESULTS
Efficacy of Intracerebroventricular AT 1 -Receptor Blockade
Intracerebroventricular angiotensin II produced a marked blood pressure response (Fig. 1) . The MAP response to intracerebroventricular angiotensin II was abolished after intracerebroventricular administration of losartan. AT 1 -receptor blockade was confined to the central nervous system, because the MAP response to intravenous angiotensin II was unaltered by intracerebroventricular losartan.
Plasma Glucose
Intravenous administration of insulin, 4 IU/kg, produced a rapid, sustained, and similar hypoglycemic response in all groups (Fig. 2) .
Plasma Epi and NE
The catecholamine responses to hypoglycemia are shown in Fig. 2 . During hypoglycemia, Epi increased 60-fold in vehicle-treated rats. This response and the corresponding AUCs were similar in all groups (P ϭ 0.73). When the linear regression data were calculated, (Table 1) , the goodness of fit (r 2 ) was close to unity in all groups. The response was similar in all groups, however, because neither the slope (k) nor the intercept with the abscissa (log a) differed. Plasma NE increased about threefold in all groups, and this response was similar in all groups. 
Blood Pressure and HR
Baseline MAP was not significantly different among groups. However, baseline HR was significantly higher after losartan and PD-123319 compared with vehicle (P Ͻ 0.05, Table 2 ). The time course of changes in MAP and HR relative to baseline values during normoglycemia are shown in Fig. 3 . During hypoglycemia, a significant but similar increase in MAP was observed in all groups, and this was associated with bradycardia in all groups. This response was significantly augmented in rats treated with PD-123319 either alone or in combination with losartan (PD-123319 vs. vehicle: P Ͻ 0.05; losartan ϩ PD-123319 vs. vehicle: P Ͻ 0.01). However, calculating the regression curves for ⌬MAP vs. ⌬HR and comparing it with the slope of the vehicle group showed that the slope was markedly (61%) and significantly greater only in the losartan ϩ PD-123319 group (P Ͻ 0.05; Fig. 4, Table 3 ).
PRA
As shown in Fig. 5 , PRA values were similar in all groups both before insulin (time 0) and during maximal sympathoadrenal activation (time 45 min).
DISCUSSION
The key finding of this study is that brain AT 1 and AT 2 receptors are not essential for the reflex increase in adrenomedullary Epi release during hypoglycemia in conscious rats. Neither the overall measure of Epi release (AUC) nor the gain of the hypoglycemia-induced reflex increase of plasma Epi was affected by central angiotensin receptor blockade. Interestingly, however, simultaneous brain AT 1 ϩ AT 2 -receptor blockade appears to increase the gain of the baroreceptor-mediated bradycardia in this model.
We previously showed that the reflex increase in plasma Epi concentration (p-Epi) during hypoglycemia is unaltered during systemic AT 1 -receptor blockade in both rats and humans. However, systemic AT 2 -receptor blockade with PD-123319 attenuates this sympathoadrenal reflex response, and combined treatment with losartan and PD-123319 or angiotensin-converting enzyme inhibition attenuates Epi release more Values are means Ϯ SE. Corresponding data pairs of plasma glucose and plasma epinephrine were fitted to the linear function log y ϭ k(x) ϩ log a, where x is plasma glucose, y the corresponding plasma epinephrine, k the slope of the linear function, and log a the intercept with the abscissa. The goodness of fit, r 2 depicts the fraction of the relation between data pairs explained by the regression line. PD, PD-123319. effectively than PD-123319 alone. These results indicate that the AT 2 receptor plays an important role in the regulation of Epi release. However, the lack of effect of centrally administered AT 1 -and AT 2 -receptor blockade on p-Epi epinephrine concentrations suggests that angiotensin II facilitation of Epi release is mediated by an AT 2 receptor-dependent effect outside the central nervous system.
The most likely site of action of peripheral AT 2 -receptor blockade on Epi release is at postsynaptic receptors in adrenal medullary chromaffin cells (15) , which in both rats and humans are mainly of the AT 2 subtype. This agrees with in vitro data from Belloni and coworkers (2) and with recent in vivo findings (16) supporting that adrenomedullary AT 2 receptors play a dominant role in the regulation of Epi release.
Other putative sites of angiotensin II facilitation of Epi release may be at more caudal levels in the central nervous system. Thus angiotensin receptors were identified in the spinal cord (22) . Moreover, the blood pressure response to intrathecal angiotensin II is blunted by both losartan and PD-123319 administered at the T9 level in rats (23) , suggesting that functionally important AT 2 receptors are located at that level. In the present study, we found that intracerebroventricular administration of dye into the right lateral ventricle reaches at least the T5 level within 1 h (data not shown). However, nuclei innervating the adrenal medulla are located at the T8-T11 level in the rat; therefore this study provides no evidence of effective blockade of spinal cord angiotensin receptors. Thus the significance of angiotensin receptors at that level in control of adrenal nerve activity remains unsettled.
The increase of NE release and MAP was similar and parallel in all groups. Moreover, hypoglycemia-induced sympathoexcitation selectively stimulates the adrenal medulla (6, 20) . Thus the observed blood pressure response was driven largely by adrenomedullary NE release. Combined AT 1 ϩ AT 2 -receptor blockade significantly increased the slope of the ⌬MAP-⌬HR linear regression curve, whereas the slope was similar to vehicle during selective blockade of either AT 1 receptors or AT 2 receptors alone. This suggests that simultaneous blockade of central AT 1 and AT 2 receptors increases the gain of the baroreflex control of HR (BRR) in this model. The mechanism of this finding is unclear at present. AT 2 receptors have not been identified in nuclei traditionally perceived to participate in angiotensin II control of the baroreflex. Central angiotensin inhibits or resets the baroreflex by two mechanisms: 1) an increased sympathetic outflow via AT 1 receptors in the rostral ventrolateral medulla (RVLM) and 2) inhibition of parasympathetic activity and consequently withdrawal of vagal inhibition of heart rate (27) . Phillips (25) proposed that neurons originating in the paraventricular nucleus of the hypothalamus (PVH) terminate in the nucleus of the solitary tract (NTS) and, through a presynaptic AT 1 receptor-mediated mechanism, blunt parasympathetic activity in the dorsal motor neuron of the vagus. Interestingly, PVH is one of only a few brain nuclei expressing a high density of AT 2 receptors (12) . This leads us to speculate whether these AT 2 receptors are involved in the observed response. The apparent involvement of both receptor subtypes might explain why simultaneous blockade of AT 1 and AT 2 receptors is required to counteract endogenous angiotensin II, i.e., increase the gain of the BRR. Several studies have shown an independent role of central AT 1 receptors in the BRR and renal sympathetic nerve activity (8, 27, 28) . Recently Matsumura and coworkers (18) demonstrated that microinjection into NTS of an AT 1 -receptor blocker, but not an AT 2 -receptor blocker, increased the sensitivity of BRR in anesthetized rats (18) . Against that finding, however, Luoh and Chan (13) , in a comparable model, demonstrated that microinjection of PD-123319 as well as losartan into NTS produced a 40-60% increased sensitivity of BRR. Those data agree with our results in support of central AT 2 receptor involvement in regulation of BRR. Interestingly, the increased sensitivity of BRR was quantitatively comparable between the two studies. However, proper baroreflex studies are warranted to further elucidate the role of AT 2 receptors in the paraventricular hypothalamic nuclei.
Despite severe sympathoadrenal activation, PRA did not change during insulin-induced hypoglycemia. Because renal sympathetic nerve activity potently stimulates renin release, the present finding is consistent with earlier studies showing that neuroglucopenia increases adrenal sympathetic nerve activity without affecting renal sympathetic nerve activity (20) .
The major limitation to this study is our inability to directly demonstrate that all relevant brain angiotensin II receptors were blocked. Generally, the conscious, unstressed animal approach limits the feasibility of directly targeting specific nuclei by microinjection of drugs. Thus precise knowledge of the concentrations of the applied receptor blockers in specific brain nuclei is not attainable using this model. Regarding AT 1 -receptor blockade, we demonstrated that 10 nmol losartan injected into the cerebral fluid effectively blocked the blood pressure response to intracerebroventricular angiotensin II (Fig. 1) , a response thought to be mediated exclusively by AT 1 receptors in nuclei of the forebrain and the lower brain stem. Regarding AT 2 -receptor blockade, the drinking response to intracerebroventricular angiotensin II is considered a paradigm of acute AT 2 receptor-mediated function. However, the literature on that issue is not consistent (29, 31, 32) , and, in our hands, neither losartan (10 nmol) nor PD-123319 (30 nmol) attenuated the drinking response to intracerebroventricular angiotensin II (unpublished observations). The applied PD-123319 was on a molar basis three times the concentration of losartan, which effectively blocked the AT 1 receptor-mediated blood pressure response. Considering that the IC 50 of losartan for the AT 1 receptor and that of PD-123319 for the AT 2 receptor are similar, i.e., 2-5 nM (11), it is highly probable that effective AT 2 -receptor blockade was obtained as well.
In summary, we found that blockade of brain AT 1 and AT 2 receptors either alone or in combination did not affect the reflex Epi release during insulin-induced hypoglycemia in conscious, chronically instrumented rats. This contrasts with the markedly attenuated Epi response observed during systemic AT 1 ϩ AT 2 -receptor blockade or ACE inhibition. Together, these results indicate that angiotensin II facilitates Epi release by an effect outside the central nervous system, most likely in the adrenal medulla. In addition, we found that simultaneous blockade of brain AT 1 and AT 2 receptors increased the gain of the BRR response in this model. These results support earlier findings that AT 2 receptors play an important role in central BRR.
Perspectives
Because the hypoglycemia-induced increase of sympathetic activity is predominantly directed to the adrenal branch of the system, this model is primarily suitable for studies on Epi release. We found that central AT 1 and AT 2 receptors are not important in the regulation of this branch of the sympathetic system. However, the finding of brain AT 1 ϩ AT 2 receptor involvement in the regulation of BRR points to an important role of AT 2 receptors in sympathetic and/or parasympathetic pathways that function independently of the aforementioned part of the sympathetic system. Considering that high insulin levels per se may slightly increase sympathetic nerve activity (1, 21) , thus complicating data interpretation, the present experimental model is not ideal for BRR studies, however. Rather, the well known pharmacological or physical means of manipulating blood pressure should be employed in future studies. By supporting earlier findings that central angiotensin II baroreceptor resetting is partly AT 2 receptor dependent, this study adds another brick to the emerging concept of AT 2 receptor involvement in cardiovascular regulation. This issue is important in a broader, clinical perspective, because converting enzyme inhibitors and selective AT 1 -receptor blockers, both widely used in hypertension, congestive heart failure, and diabetes mellitus, have opposite effects on AT 2 receptor function, that is, decreased stimulation and increased stimulation, respectively. Thus uncovering AT 2 receptor function might help explain clinical differences between these drugs.
